University of California, San Francisco |
Webinar Date: Wednesday, August 25, 2021 Please join and bring your clinical questions for this interactive office hour session hosted by the National Clinician Consultation Center (NCCC) and the Health Resources & Services Administration’s Bureau of Primary Health Care (HRSA BPHC). The interplay between substance use, HIV, and hepatitis C virus (HCV) present unique challenges and […]
Archive by Author
Webinar: Management of Stimulant Use Disorder
Webinar Date: Tuesday, April 27, 2021 Please join the National Clinician Consultation Center (NCCC) in partnership with the Health Resources & Services Administration’s Bureau of Primary Health Care for this webinar, developed for health center clinicians. The misuse of stimulants, comprised of methamphetamine, cocaine, and other amphetamines, is a growing public health crisis across the United […]
Information about COVID-19 for Clinicians
Because of the rapidly-changing understanding of COVID-19, here are some of the key links to guidances for clinicians: Interim Guidance for COVID-19 and Persons with HIV Open Link | From AIDSinfo (DHHS) HRSA HIV/AIDS Bureau (HAB) Frequently Asked Questions Open Link | From Health Resources & Services Administration (HRSA) Information for Healthcare Professionals Open Link […]
CCC Update to FDA Notice: Dolutegravir and Post-Exposure Prophylaxis (PEP)
**PLEASE NOTE: This statement is now outdated. We will provide updates when additional data is available. In the meantime, please reference the HHS Perinatal Guidelines for more information on dolutegravir in pregnancy and pre-conception: https://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0** On May 30, 2018 the HHS Antiretroviral Guidelines Panels issued recommendations on the use of dolutegravir for treatment of adults and […]
CCC Response to FDA Notice: Dolutegravir and Post-Exposure Prophylaxis (PEP)
The U.S. Food and Drug Administration (FDA) alerted the public on 5/18/18 that serious cases of neural tube birth defects have been reported in babies born to women living with HIV who were treated with dolutegravir at the time of becoming pregnant or early in the first trimester (https://fda.gov/Drugs/DrugSafety/ucm608112.htm). Until more information is available, we […]
National HIV Testing Day 2017: Test Your Way. Do It Today!
HIV Testing Is the First Step to Care National HIV Testing Day (NHTD) is an annual campaign encouraging people of all ages to get tested for HIV and know their status. In the United States, an estimated 1.1 million people are living with HIV, and 1 in 7 of them is unaware of their diagnosis […]
PEPline Crowdfunding Update
PEPline Crowdfunding Update Despite the invaluable service the PEPline provides, federal funding has not been able to keep up with the increased demand for expert consultations. For those who need the service, we fear this will result in less-than-optimal service, as it is incredibly important to receive timely expert guidance in order to prevent HIV […]
National Asian & Pacific Islander HIV/AIDS Awareness Day 2017
May 19th is the 13th annual National Asian & Pacific Islander HIV/AIDS Awareness Day, originally founded by the Banyan Tree Project with support from the Centers for Disease Control and Prevention (CDC) to end stigma, prevent HIV, and help A&PIs living with HIV. This year’s campaign slogan is “Saving face can’t make you safe. Talk […]
Hepatitis Awareness Month 2017
In the United States, over 4.4 million people are living with chronic viral hepatitis (CDC). Viral hepatitis can lead to increased risk for various health conditions, such as chronic liver disease and cancer, and currently causes more than 200,000 deaths in the United States (NASEM). Chronic liver disease/cirrhosis is the 4th most common cause of death […]
Introducing our PEPline Crowdfunding Campaign!
Clinical Advice Service on Occupational Exposures to HIV Begins New Campaign to Meet National Need Every day thousands of workplace exposures to HIV, hepatitis B and hepatitis C occur in the United States. Even with great advances in HIV and viral hepatitis prevention and treatment, exposure to bloodborne pathogens is a real risk in many […]